

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims:

1-47. (Cancelled)

48. (Currently Amended) A method for treating a human patient suffering from stroke, said method comprising administering to said patient directly at the site of said stroke a ~~substantially pure population of human CD34+/-, Lin- cells from umbilical cord blood (UCB) or peripheral blood, wherein said CD34+/-, Lin- cells are separated from other mononuclear cells present in said UCB or said peripheral blood prior to said administering and~~ wherein said administering ~~the administration of said cells~~ results in measurable stroke recovery in said patient.

49. (Previously Presented) The method of claim 48, wherein said cells are isolated from UCB.

50. (Previously Presented) The method of claim 48, wherein said cells are isolated from peripheral blood.

51. (Currently Amended) The method of claim 48 further comprising concurrently with or following administration of said CD34+/-, Lin- cells administering a growth factor to said

patient.

52. (Previously Presented) The method of claim 51, wherein said growth factor is selected from the group consisting of oncostatin M, FGF, neurotrophin, IGF, CNTF, EGF, TGF-beta, LIF, interleukins, PDGF, and VEGF.

53. (Currently Amended) The method of claim 48, wherein said CD34+/-, Lin- cells are allogeneic cells.

54. (Currently Amended) The method of claim 48, wherein said CD34+/-, Lin- cells are autologous cells.

55. (Currently Amended) The method of claim 48, wherein said CD34+/-, Lin- cells are characterized as negative for expression of CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and positive for expression of flk-1, CD45, CXCR4, and MDR.

56. (Previously Presented) The method of claim 48, wherein said method comprises administering a population of cells consisting of human CD34+/-, Lin- cells.

57. (Currently Amended) A method for treating a human patient suffering from stroke, said method comprising the steps of:

- (a) separating ~~obtaining a substantially pure population of~~ CD34+/-, Lin- cells from

other mononuclear cells present in umbilical cord blood (UCB) or peripheral blood using a selection element; and

(b) administering said CD34+/-, Lin- cells to said patient directly at the site of said stroke, wherein said administering ~~the administration of said cells~~ results in measurable stroke recovery in said patient.

58. (Previously Presented) The method of claim 57, wherein said selection element comprises an antibody.

59. (Withdrawn) The method of claim 57, wherein step (a) is performed using positive selection.

60. (Previously Presented) The method of claim 57, wherein step (a) is performed using negative selection.

61. (Currently Amended) The method of claim 57, wherein said CD34+/-, Lin- cells are isolated from UCB.

62. (Currently Amended) The method of claim 57, wherein said CD34+/-, Lin- cells are isolated from peripheral blood.

63. (Currently Amended) The method of claim 57 further comprising concurrently with

or following administration of said CD34+/-, Lin- cells administering a growth factor to said patient.

64. (Previously Presented) The method of claim 63, wherein said growth factor is selected from the group consisting of oncostatin M, FGF, neurotrophin, IGF, CNTF, EGF, TGF-beta, LIF, interleukins, PDGF, and VEGF.

65. (Currently Amended) The method of claim 57, wherein said CD34+/-, Lin- cells are allogeneic cells.

66. (Currently Amended) The method of claim 57, wherein said CD34+/-, Lin- cells are autologous cells.

67. (Currently Amended) The method of claim 57, wherein said CD34+/-, Lin- cells are characterized as negative for expression of CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and glycophorin A, and positive for expression of flk-1, CD45, CXCR4, and MDR.

68. (Previously Presented) The method of claim 57, wherein said method comprises administering a population of cells consisting of human CD34+/-, Lin- cells.